Close
Acrivon Therapeutics, a clinical stage precision medicine company, reported its financial results for Q2 2024, highlighting significant advancements in its drug development pipeline. The company is focused on utilizing its Acrivon Precision Predictive Proteomics (AP3) platform to match therapies with patients whose diseases are predicted to be sensitive to specific treatments. Acrivon plans to present additional clinical data for its lead asset, ACR-368, at the upcoming ESMO conference in September 2024.
The report emphasized the promising results from the Phase 2 trial of ACR-368, which showed a 50% overall response rate in patients with gynecological cancers. Additionally, Acrivon is on track to initiate a Phase 1 clinical study for ACR-2316, a selective WEE1/PKMYT1 inhibitor, further showcasing the company's commitment to addressing high unmet needs in cancer treatment. The financial outlook remains strong, with $220.4 million in cash expected to support operations into 2026.
• Acrivon plans to present clinical data at the ESMO conference.
• ACR-368 shows a 50% response rate in gynecological cancer patients.
Acrivon utilizes precision medicine to match therapies to patients based on predicted sensitivity.
Acrivon's AP3 platform employs predictive proteomics to identify patients likely to benefit from specific therapies.
Acrivon's ACR-368 OncoSignature test predicts sensitivity in patients with ovarian and endometrial cancers.
The company leverages its AP3 platform to develop therapies tailored to patients' specific cancer profiles.
Business Insider 14month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
Key AI Highlights in this Article
Key AI Terms Mentioned in this Article
Companies Mentioned in this Article
